{
    "clinical_study": {
        "@rank": "127608", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102", 
                "arm_group_type": "Experimental", 
                "description": "MK-3102 12.5 mg or 25 mg capsule orally once a week for 54 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24), will receive matching placebo to glipizide in a blinded manner during Phase B of the study (Week 24 through Week 54)."
            }, 
            {
                "arm_group_label": "Placebo to MK-3102", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to MK-3102 orally once a week for 54 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24), will receive glipizide in a blinded manner during Phase B of the study (Week 24 through Week 54)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of MK-3102 in participants\n      with type 2 diabetes mellitus and moderate or severe chronic renal insufficiency or end\n      stage renal disease on dialysis with inadequate glycemic control.  The primary hypothesis of\n      the study is that MK-3102 compared to placebo produces greater reduction in glycosylated\n      hemoglobin (A1C) after 24 weeks."
        }, 
        "brief_title": "A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Kidney Diseases", 
                "Renal Insufficiency", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes mellitus and be at least 30 years of age\n\n          -  Moderate or severe chronic renal insufficiency or end stage renal disease on dialysis\n\n          -  Meet one of the following criteria:\n\n               1. is currently not on an antihyperglycemic agent (AHA) and has A1C >=7% and <=10%\n                  at screening\n\n               2. is currently on a single oral AHA or low-dose dual oral combination AHA and has\n                  A1C >=6.5% and <=9% at screening\n\n               3. is currently on a stable insulin regimen (>= 15 U/day) for >= 10 weeks, with no\n                  oral AHA, and has A1C >=7.5% and <=10% and FPG >130 mg/dL at screening\n\n          -  (1) Male; (2) female not of reproductive potential; or (3) female of reproductive\n             potential who agrees to remain abstinent or use alone or in conjunction with their\n             partner 2 methods of contraception to prevent pregnancy during the study and for 28\n             days after the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  Treated with any incretin mimetic or thiazolidinedione (TZD) within 12 weeks prior to\n             screening or with MK-3102 at any time prior to study participation\n\n          -  History of hypersensitivity to a dipeptidyl peptidase IV (DPP-4) inhibitor\n\n          -  History of intolerance or hypersensitivity to glipizide or insulin glargine or any\n             contraindication to glipizide or insulin glargine\n\n          -  On a weight loss program and is not in the maintenance phase, or has been on a weight\n             loss medication in the past 6 months, or has undergone bariatric surgery within 12\n             months prior to study participation\n\n          -  Undergone a surgical procedure within 4 weeks prior to screening or has planned major\n             surgery during the trial\n\n          -  On or likely to require treatment for >=2 consecutive weeks or repeated courses of\n             corticosteroids (note: inhaled, nasal or topical corticosteroids are permitted)\n\n          -  Currently being treated for hyperthyroidism or is on thyroid replacement therapy and\n             has not been on a stable dose for at least 6 weeks\n\n          -  If on dialysis, does not regularly adhere to dialysis schedule\n\n          -  Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class IV\n\n          -  Medical history of active liver disease (other than non-alcoholic hepatic steatosis),\n             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Human immunodeficiency virus (HIV)\n\n          -  New or worsening coronary heart disease, congestive heart failure, myocardial\n             infarction, unstable angina, coronary artery intervention, stroke, or transient\n             ischemic neurological disorder within the past 3 months\n\n          -  Poorly controlled hypertension\n\n          -  Severe active peripheral vascular disease\n\n          -  History of malignancy <=5 years prior to study participation, except for adequately\n             treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n\n          -  Clinically important hematological disorder (such as aplastic anemia,\n             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n          -  Positive pregnancy test\n\n          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs during the\n             trial, including 28 days following the last dose of study drug\n\n          -  User of recreational or illicit drugs or has had a recent history of drug abuse or\n             routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or\n             engages in binge drinking"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698775", 
            "org_study_id": "3102-019", 
            "secondary_id": "2012-002332-85"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-3102", 
                "description": "Participants with moderate renal insufficiency will receive one MK-3102 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one MK-3102 12.5 mg capsule orally once a week", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to MK-3102", 
                "description": "Matching placebo to MK-3102 capsule administered orally once a week", 
                "intervention_name": "Placebo to MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo to MK-3102"
                ], 
                "description": "Participants may receive open-label glipizide as rescue therapy during Phase A (up to Week 24) of the study. During Phase B of the study (after Week 24), participants who did not receive insulin or open-label glipizide rescue therapy during Phase A will receive glipizide 2.5 mg or 5 mg capsule or matching placebo as blinded therapy at a starting dose of 2.5 mg once daily in the morning prior to the morning meal and electively titrated up to a maximum of 20 mg/day based on glycemic control.", 
                "intervention_name": "Glipizide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Glucotrol", 
                    "Glucotrol XL"
                ]
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo to MK-3102"
                ], 
                "description": "Matching placebo to glipizide", 
                "intervention_name": "Placebo to glipizide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo to MK-3102"
                ], 
                "description": "Participants on insulin therapy at screening will continue insulin therapy during the study.  Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.", 
                "intervention_name": "Insulin", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glipizide", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91910"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roseville", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95661"
                    }, 
                    "name": "Call for Information (Investigational Site 0016)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95825"
                    }, 
                    "name": "Call for Information (Investigational Site 0020)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "Call for Information (Investigational Site 0021)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91307"
                    }, 
                    "name": "Call for Information (Investigational Site 0015)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Doral", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33172"
                    }, 
                    "name": "Call for Information (Investigational Site 0009)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33174"
                    }, 
                    "name": "Call for Information (Investigational Site 0022)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Macon", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31217"
                    }, 
                    "name": "Call for Information (Investigational Site 0001)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockport", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04856"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Rochelle", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10801"
                    }, 
                    "name": "Call for Information (Investigational Site 0019)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37408"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Corpus Christi", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78414"
                    }, 
                    "name": "Call for Information (Investigational Site 0010)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77043"
                    }, 
                    "name": "Call for Information (Investigational Site 0025)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }, 
                    "name": "Call for Information (Investigational Site 0013)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77074"
                    }, 
                    "name": "Call for Information (Investigational Site 0018)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77450"
                    }, 
                    "name": "Call for Information (Investigational Site 0011)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sealy", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77474"
                    }, 
                    "name": "Call for Information (Investigational Site 0017)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sugar Land", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77479"
                    }, 
                    "name": "Call for Information (Investigational Site 0024)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Temple", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76502"
                    }, 
                    "name": "Call for Information (Investigational Site 0008)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Federal Way", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98003"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andina Hrabar", 
                    "phone": "385 14878400"
                }, 
                "facility": {
                    "address": {
                        "city": "Zagreb", 
                        "country": "Croatia"
                    }, 
                    "name": "Merck Sharp & Dohme d.o.o"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "420 233010213"
                }, 
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Merck Sharp and Dohme s.r.o."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lai Hung Jen", 
                    "phone": "886 2 2730 0030"
                }, 
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Merck Sharp & Dohme (Asia) Ltd."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "36 1 457 8522"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "MSD Pharma Hungary Kft."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ofer Sharon", 
                    "phone": "972 9 9539310"
                }, 
                "facility": {
                    "address": {
                        "city": "Hod Hasharon", 
                        "country": "Israel"
                    }, 
                    "name": "Merck Sharp & Dohme Co. Ltd."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Boon Hock Yeoh", 
                    "phone": "60 377181723"
                }, 
                "facility": {
                    "address": {
                        "city": "Petaling Jaya", 
                        "country": "Malaysia"
                    }, 
                    "name": "MSD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cesar Recto", 
                    "phone": "632 784 9500"
                }, 
                "facility": {
                    "address": {
                        "city": "Makati", 
                        "country": "Philippines"
                    }, 
                    "name": "Merck Sharp & Dohme (I.A.) Corporation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Adam Czernik", 
                    "phone": "48 22 4784324"
                }, 
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "MSD Polska Sp. Z o.o."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Koroleva", 
                    "phone": "7 0959410000"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Merck Sharp & Dohme IDEA, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Croatia", 
                "Czech Republic", 
                "Hong Kong", 
                "Hungary", 
                "Israel", 
                "Malaysia", 
                "Philippines", 
                "Poland", 
                "Russian Federation", 
                "Serbia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in glycosylated hemoglobin (A1C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 24 (up to 24 weeks)"
            }, 
            {
                "measure": "Percentage of participants who discontinued from the study due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 24 (up to 24 weeks)"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 28 days following the last dose of study therapy (up to 58 weeks)"
            }, 
            {
                "measure": "Percentage of participants who discontinued from the study due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 54 (up to 54 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in A1C", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }, 
            {
                "measure": "Change from baseline in FPG", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }, 
            {
                "measure": "Change from baseline in estimated glomerular filtration rate (eGFR)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in eGFR", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 54"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}